Posted by Michael Wonder on 10 Sep 2018
Canadian Dermatology Association and Canadian Society of Allergy and Clinical Immunology issue joint statement against the Canadian Agency for Drugs and Technologies in health recommendation
10 September 2018 - Many Canadian eczema sufferers are dealt a difficult blow; many patients face a future with no access to promising new treatment.
The Canadian Dermatology Association and the Canadian Society of Allergy and Clinical Immunology jointly express disappointment with the Canadian Agency for Drugs and Technologies in Health’s recommendation to not reimburse the cost of a new and promising drug, Dupixent (dupilumab) for patients suffering from moderate to severe eczema.
The CADTH recommendation impacts patients on public insurance plans.
